The following provides essential safety information on the unapproved use of baricitinib under the Emergency Use Authorization.
WARNINGS
There are limited clinical data available for baricitinib in pediatric patients 2 to less than 18 years of age hospitalized with COVID-19 requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO.
Serious Infections
There is limited information regarding use of baricitinib in patients with COVID-19 and concomitant active serious infections.
Serious infections, including viral reactivation, have occurred in patients with COVID-19 receiving baricitinib. Avoid the use of baricitinib with known active tuberculosis. Consider if the potential benefits outweigh the potential risks of baricitinib treatment in patients with active serious infections other than COVID-19 or chronic/recurrent infections.
Thrombosis
Serious venous thrombosis, including pulmonary embolism have been observed in COVID-19 patients treated with baricitinib and are known adverse drug reactions of baricitinib. If clinical features of deep vein thrombosis or pulmonary embolism occur, patients should be evaluated promptly and treated appropriately.
Abnormal Laboratory Values
There is limited information regarding use of baricitinib in patients with COVID-19 and any of the following clinical findings: absolute neutrophil count (ANC) <1000 cells/mm3, absolute lymphocyte count (ALC) <200 cells/mm3, and hemoglobin <8 g/dL.
Evaluate estimated glomerular filtration rate (eGFR), liver enzymes, and complete blood count at baseline and thereafter according to local patient management practice. Monitor closely when treating patients with abnormal baseline and post-baseline laboratory values. Follow dosage modifications as recommended in the Fact Sheet for Healthcare Providers for patients with abnormal renal, hematological and hepatic laboratory values. Manage patients according to routine clinical guidelines.
Vaccinations
Avoid use of live vaccines with baricitinib.
Hypersensitivity
If a serious hypersensitivity occurs, discontinue baricitinib while evaluating the potential causes of the reaction.
See Warnings and Precautions in the FDA-approved full Prescribing Information and Medication Guide for additional information on risks associated with baricitinib treatment.
SERIOUS SIDE EFFECTS
Serious venous thrombosis, including pulmonary embolism, and serious infections have been observed in COVID-19 patients treated with baricitinib and are known adverse drug reactions of baricitinib.
ADVERSE REACTIONS
During the first 29 days in COVID-19 clinical trials, adverse reactions that occurred in ≥1% of patients treated with baricitinib 4mg vs placebo, respectively, were alanine aminotransferase (ALT) ≥3 x upper limit of normal (ULN) (18.1% vs 16.0%), aspartate aminotransferase (AST) ≥3 x ULN (11.8% vs 9.4%), thrombocytosis >600,000 cells/mm3 (7.9% vs 4.6%), creatine phosphokinase (CPK) >5 x ULN (4.5% vs 4.7%), neutropenia <1000 cells/mm3 (2.2% vs 1.8%), deep vein thrombosis (1.5% vs 1.4%), pulmonary embolism (1.5% vs 0.8%), and urinary tract infection (1.5% vs 1.0%).
USE IN SPECIFIC POPULATIONS
Pregnancy
Baricitinib should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.
Renal Impairment
There are limited data for baricitinib in patients with severe renal impairment. Baricitinib is not recommended for patients who are on dialysis, have end-stage renal disease, or have acute kidney injury.
Hepatic Impairment
Baricitinib has not been studied in patients with severe hepatic impairment. Baricitinib should only be used in patients with severe hepatic impairment if the potential benefit outweighs the potential risk.
Please see Fact Sheet for Healthcare Providers and Fact Sheet for Patients, Parents and Caregivers (English) or Fact Sheet for Patients, Parents and Caregivers (Spanish). Please also see the FDA Letter of Authorization on the authorized use of baricitinib.
BC HCP EUA ISI 11MAY2022